Mylan posts quarterly profit compared to year-earlier loss
Aug 6 (Reuters) - Mylan NV MYL.O reported a second-quarter profit on Thursday, helped in part by strong sales of its newly launched products such as asthma drug Wixela.
The drugmaker reported net earnings of $39.4 million, or 8 cents per share, in the three months ended June 30, compared to a loss of $168.5 million, or 33 cents per share, a year earlier.
Total revenue of the company, whose merger with Pfizer Inc's PFE.N off-patent branded drugs unit has been delayed by the pandemic, fell to $2.73 billion from $2.85 billion.
(Reporting by Manojna Maddipatla and Trisha Roy in Bengaluru; Editing by Shounak Dasgupta)
((email@example.com; +91 8061822700;))
In This StoryPFE
Latest Markets Videos
- Tesla removed from S&P 500 ESG index on autopilot, discrimination concerns
- Fed could cut rates in 2023, 2024 once inflation under control -Bullard
- US STOCKS-Wall Street ends sharply lower as Target and growth stocks sink
- Powell says Fed to 'keep pushing' rates higher until clear inflation is falling